Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

554
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
554
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

398
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

839
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

812
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
812

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort.

American journal of preventive cardiology·2026
Same author

Combined LDL-C, Lp(a), and hsCRP Assessment Predicts ASCVD in the Multiethnic HELIUS Cohort.

Journal of the American College of Cardiology·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention.

European journal of preventive cardiology·2026
Same author

Reduced postprandial lipid accumulation in circulating monocytes by olezarsen attenuates pro-inflammatory changes in hypertriglyceridemic patients.

European heart journal open·2026
Same author

Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.

Circulation·2026

Related Experiment Video

Updated: Mar 29, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Current therapies for lowering lipoprotein (a).

Julian C van Capelleveen1, Fleur M van der Valk1, Erik S G Stroes2

  • 1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Journal of Lipid Research
|December 6, 2015
PubMed
Summary

Lipoprotein (a) [Lp(a)] is linked to cardiovascular disease (CVD) risk. Current therapies to lower Lp(a) show varied success, highlighting the urgent need for potent Lp(a)-lowering strategies to confirm cardiovascular benefits.

Keywords:
apolipoproteinsdrug therapydrug therapy/hypolipidemic drugsdyslipidemiaslipoprotein(a)lipoproteins

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Related Experiment Videos

Last Updated: Mar 29, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Lipoprotein (a) [Lp(a)] is a unique human plasma lipoprotein.
  • Lp(a) comprises apoB and apo(a) glycoprotein.
  • Elevated Lp(a) levels are strongly associated with increased cardiovascular disease (CVD) risk.

Purpose of the Study:

  • To review past and present therapies targeting Lp(a) reduction.
  • To assess the efficacy of existing Lp(a)-lowering agents.
  • To emphasize the need for novel Lp(a)-lowering strategies.

Main Methods:

  • Review of existing literature on Lp(a) therapies.
  • Analysis of the success rates of various therapeutic approaches.
  • Identification of challenges in demonstrating clinical benefit.

Main Results:

  • Therapeutic agents for lowering Lp(a) have demonstrated varying degrees of success.
  • A significant gap exists between Lp(a) lowering and proven cardiovascular benefit.
  • Current strategies require further refinement for optimal outcomes.

Conclusions:

  • Effective Lp(a) reduction remains a therapeutic challenge.
  • Confirmation of cardiovascular benefit from Lp(a) lowering is the next critical step.
  • Development of highly specific and potent Lp(a)-lowering strategies is urgently required.